The prevalence of haemophilia is rising. More innovative items are getting approved and released, and important players are working together strategically. The MENA biologics & biosimilars market is expanding as a result of expanding strategic partnerships with top pharmaceutical firms and research institutions for the creation of innovative biosimilars.
The market for MENA biologics and biosimilars is anticipated to reach US$ 442.5 million in 2020 and grow at a CAGR of 3.9% from 2020 to 2027.
Prominent Players in the MENA Biologics Industry:
1. F. Hoffmann-la Roche Ag: Established on October 1st, 1896. Headquarters in the United States. Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar.
2. Regeneron Pharmaceuticals, Inc.: Founded 1988 . Headquarters in the United States. The company Regeneron Pharmaceuticals finds, creates, and sells medicines to treat inflammation, cancer, cardiovascular disease, and eye disorders. The company markets a number of medications, including Kevzara for rheumatoid arthritis, Praluent for decreasing LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Eylea for wet age-related macular degeneration and other eye illnesses. With Sanofi, other partners, and independently, Regeneron is also working on the development of monoclonal and bispecific antibodies. It also has earlier-stage collaborations with companies exploring cutting-edge technologies including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). Checkmate Pharmaceuticals, Inc. has been successfully purchased by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), strengthening the company's commitment to immuno-oncology and introducing a novel modality to its portfolio of potential combination-ready therapies for challenging-to-treat tumours.
3. Pfizer, Inc.: Founded in 1848. United States headquarters. One of the biggest pharmaceutical companies in the world, Pfizer with yearly sales of around $50 billion (excluding COVID-19 product sales). The company used to sell a wide variety of chemicals and healthcare items, but today the majority of its sales come from prescription medications and vaccinations. Prevnar 13, an anti-pneumococcal vaccination, Ibrance, Eliquis, and Xeljanz are some of the best-selling medications. Pfizer markets these goods internationally, with close to 50% of its overall sales coming from overseas markets. Emerging markets have a significant role in global sales. The purchase gives Pfizer access to a range of promising calcitonin products, including 3% of Biohaven Ltd.
4. Amgen, Inc.: Established in 1980. United States headquarters. Amgen is a pioneer in biotechnology-based human medicines with a track record in supportive care for cancer patients and renal disease. Flagship medications include the immune system boosters Neupogen and Neulasta, the red blood cell boosters Epogen and Aranesp, and the inflammatory disease medications Enbrel and Otezla. Amgen released Vectibix, its first cancer treatment, in 2006. It also sells the bone-strengthening medications Prolia/Xgeva (authorised in 2010) and Evenity (released in 2019).
5. Sanofi S.A.: Established in 1973. Headquarters in France, in Paris. Therapeutics created and distributed with patients' needs in mind. The business sells consumer healthcare items, vaccines for humans, animal health goods, and drugs for diabetes and cancer. Sanofi has finished buying Provention Bio, Inc.
6. Takeda Pharmaceutical Company Limited: Built in 1925. Headquarters in Japan. With a revenue of JPY 4 trillion in fiscal 2022, Takeda Pharmaceutical Co Ltd is the pharmaceutical firm in Japan. Oncology, gastroenterology, neuroscience, rare illnesses, and plasma-derived medicines are the company's five major therapeutic areas, which together provide more than 80% of its revenue. It has a well-diversified global footprint, with 50% coming from the United States, 20% from Japan, 20% from Europe, and 20% from Canada. Nimbus Lakshmi (Dec 2022), Adaptate Biotherapeutics (Jan 2022), and GammaDelta Therapeutics (Oct 2021) are the most recent acquisitions.
*Definition: A biosimilar is a biologic that is highly similar to, and has no clinically meaningful differences from, another biologic that's already FDA-approved
